For over a decade, a staggering 80% of clinical trials have faced delays because they can’t recruit enough patients. These global benchmarks for clinical trial enrollment metrics aren’t just numbers in a report. They directly dictate how fast life-saving treatments get to the people who need them. We have to learn from these past failures, because right now we’re just repeating the same enrollment mistakes over and over again.
Key Takeaways
- A massive disconnect in outreach means only 7% of potential trial participants are ever even screened.
- Sites are hitting just 25% of their patient enrollment targets on average, pointing to huge operational problems at the ground level.
- The average 100-day wait from site initiation to the first patient enrolled is a critical bottleneck that demands better upfront planning.
- Oncology trials have the worst enrollment rates, hitting just 25% of their target in the planned time.
- Sponsors must invest in AI-driven patient finding tools and decentralized trial models to fix enrollment speed and diversity.
The Startling Reality: Only 7% of Potential Participants Screened
The recruitment funnel has a colossal leak right at the top. A 2025 Tufts CSDD report shows that we only manage to screen a mere 7% of individuals we identify as potentially eligible for a trial. This global benchmark should be alarming for every sponsor and researcher. It tells me our outreach strategies, whether it’s old-school advertising or digital campaigns, are either targeting the wrong people or we’re just plain bad at explaining why the trial matters. My own work on early-phase oncology trials confirms this every day. The problem often starts with eligibility criteria that are so strict they don’t match any real-world patient, or we create recruitment materials that are so dense with jargon that a normal person can’t make heads or tails of it. We’re spending millions developing the drug but practically nothing on making the trial itself accessible.
Site Underperformance: Just 25% of Enrollment Targets Met
But the problems don’t stop once you find someone. Even after sites are activated, the performance is grim. Across the board, research sites manage to hit only 25% of their committed patient enrollment targets. That figure is unacceptable. When a site promises 10 patients and delivers 2, the entire study timeline and budget gets thrown into chaos. This often points to systemic issues, not just a lack of effort from the site staff. Sites are often over-projected during feasibility studies or they lack adequate sponsor support for patient identification and pre-screening. In fact, a 2024 analysis by the Association of Clinical Research Organizations (ACRO) found that poor site training and overworked coordinators were the main culprits. We have to stop asking sites “how many can you enroll?” and start asking “what support do you need to actually do it?” The current model is broken, and this 25% figure proves it.
| Feature | Current State | AI-driven Tools | Decentralized Models |
|---|---|---|---|
| Addresses 7% Screened Issue | ✗ No | ✓ Improves identification | ✓ Improves outreach |
| Addresses 25% Site Target Issue | ✗ No | ✓ Supports site efficiency | ✓ Reduces site burden |
| Addresses 100-Day Bottleneck | ✗ No | ✓ Accelerates processes | ✓ Simplifies startup |
| Addresses Oncology Enrollment | ✗ No (25% rate) | ✓ Targets specific patients | ✓ Increases access |
| Improves Enrollment Speed | ✗ Slow | ✓ Significantly improves | ✓ Significantly improves |
| Improves Enrollment Diversity | ✗ Limited | ✓ Broadens reach | ✓ Broadens reach |
| Requires Sponsor Investment | ✗ Ineffective current spend | ✓ Prioritized investment | ✓ Prioritized investment |
The 100-Day Bottleneck: Site Initiation to First Patient In
The time from site initiation to the first patient enrolled (FPI) is a critical and incredibly frustrating benchmark. Globally, it takes about 100 days. That’s a three-month delay that significantly drags down the whole timeline before a single patient is even randomized. It’s not just about getting regulatory documents signed. This delay is usually caused by clunky startup processes, endless back-and-forth on contracts, and sites just not being ready to go. If you have a big Phase 3 study with 100 sites, and each one takes 100 days to get its first patient, you’ve added months of dead time to the project. A recent IQVIA report on 2025 development trends showed that just optimizing site activation could shave weeks off this number. My take? Sponsors have to invest in dedicated site activation teams and use technology that lets them exchange and approve documents faster. The old-fashioned, one-step-at-a-time approach to site startup is just too slow for modern medicine.
Oncology’s Persistent Challenge: 25% Enrollment Within Timeline
While every therapeutic area struggles, oncology trials are in a class of their own for failure. On average, these studies enroll only 25% of their target within the planned timeline. It’s a painful statistic, especially given how urgently we need new cancer therapies. The reasons are complicated: incredibly specific eligibility criteria, patients who are too sick to participate, and a crowded field of competing trials. A recent article in the New England Journal of Medicine even discussed how molecularly targeted therapies are making the eligible patient pool even smaller. The emotional burden on patients and their families often makes participating in a complex trial seem overwhelming. We need to rethink how we present these studies, focusing on patient support and reducing the logistical nightmare, not just on the scientific details. The old idea that desperate patients will always find a way to an oncology trial is just plain wrong, and the data proves it.
Challenging Conventional Wisdom: The Overreliance on Investigator Networks
For years, the industry has believed that a good investigator with a large practice is all you need for successful enrollment. Investigator commitment is important, but it’s not the primary driver of success in 2026. I strongly disagree with that premise. The data we’ve just been through, like the 7% screening rate and 25% site performance, shows that just relying on a doctor’s personal patient list isn’t nearly enough. Patient populations are incredibly diverse, and where people with a certain disease live can vary wildly. Plus, with today’s complex protocols, even a huge patient pool might only produce a handful of people who are actually eligible. Based on years of watching trials fail, sponsors have to actively invest in multiple channels for finding patients that go far beyond a site’s rolodex. That means using real-world data (RWD) to find and contact the right people, using AI to scan electronic health records (with all the right privacy controls, of course), and using decentralized clinical trial (DCT) models to reach people who don’t live near a big research hospital. Sites need proactive support from the sponsor to find patients. We need to embrace a data-driven, patient-first approach to recruitment.
So what do these global clinical trial enrollment metrics tell us? They show an industry that’s stuck grappling with the same old inefficiencies. Fixing these problems requires a fundamental change in strategy, one that uses technology, designs trials for actual patients, and gives real support to sites. Faster, more effective enrollment isn’t just a goal. The future of medical innovation depends on it.
Average patient screening success rate?
Only about 7% of people identified as potential candidates for a clinical trial are actually screened. This low rate shows huge gaps in our initial outreach and how we assess eligibility.
Time from site initiation to first patient in?
The average time from getting a site started to enrolling the first patient is about 100 days. This three-month period is a major bottleneck that slows down trial timelines.
Therapeutic area with the biggest enrollment challenges?
Oncology trials consistently have the worst enrollment problems. Many studies only get to 25% of their enrollment goal in the planned time, often because of complex eligibility rules and the poor health of potential participants.
Percentage of enrollment targets that sites actually meet?
On average, trial sites around the world only hit 25% of the patient enrollment numbers they commit to. This points to widespread problems with how sites are evaluated for feasibility, supported, or managed.
What strategies can improve enrollment metrics?
To improve enrollment, you need to do several things at once: use real-world data to find patients, bring in AI-powered recruitment tools, adopt decentralized trial models, and give much stronger support and training to your research sites.
